Answers are grounded in this paper and cite their sources.
(1) Background: Peripheral norepinephrine enables timely vasopressor initiation, but local safety remains uncertain. This rapid review mapped administration practices and local adverse events in critically ill adults. (2) Methods: Following Joanna Briggs Institute and Cochrane rapid review guidance and PRISMA 2020 (OSF: 10.17605/OSF.IO/6VH9E), PubMed, MEDLINE Complete and CINAHL Complete were searched through 22 August 2026 (PubMed re-run with corrected syntax within this limit). Included syntheses were citation-searched. Short peripheral intravenous and midline catheters were analysed separately; peripherally inserted central catheters were classified as central access. (3) Results: Thirty-nine sources were included (27 primary studies, seven syntheses, five normative documents); three reports were unavailable. In 14 norepinephrine-specific reports using short peripheral catheters, source-defined extravasation or infiltration occurred in 0–5.6% of patients or infusions, and with midline catheters in one of 472 episodes; composite local events were analysed separately. Serious injury was inconsistently assessed; one fasciotomy occurred among 3734 patients in a mixed-agent cohort. Confidence was low to very low for all outcomes. (4) Conclusions: Observational evidence suggests that peripheral norepinephrine is feasible in selected critically ill adults under structured monitoring and extravasation-response protocols, with infrequent, mostly minor events, but does not establish comparative safety or universal concentration, dose or duration limits.
No takes yet. Share an insight, caveat, or question.
Serápio et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: